<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734926</url>
  </required_header>
  <id_info>
    <org_study_id>ZSP1241-18-01</org_study_id>
    <nct_id>NCT03734926</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of ZSP1241 in Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Zhongsheng Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Zhongsheng Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and&#xD;
      determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular&#xD;
      carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other&#xD;
      advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ZSP1241 in single dose ascending (SAD) and multiple dose ascending (MAD) as measured by assessment of maximum tolerated dose (MTD), dose limiting toxicity (DLT) and treatment emergent adverse events (TEAEs)</measure>
    <time_frame>At Day 7 for SAD Part and At day 28 after for MAD part</time_frame>
    <description>Participant with TEAEs assessed by CTCAE V5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP).</measure>
    <time_frame>Screening, Day 28 of Cycle 1 (28 days), then every 6 weeks for hepatocellular carcinoma or 8 weeks for other advanced solid tumors, until disease progression or discontinuation from study (up to 18 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR).</measure>
    <time_frame>Screening, Day 28 of Cycle 1 (28 days), then every 6 weeks for hepatocellular carcinoma or 8 weeks for other advanced solid tumors, until disease progression or discontinuation from study (up to 18 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ZSP1241</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.</time_frame>
    <description>Defined as maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ZSP1241</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.</time_frame>
    <description>Defined as time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of ZSP1241</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.</time_frame>
    <description>Defined as minimum observed plasma concentration during the dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t of ZSP1241</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.</time_frame>
    <description>Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ of ZSP1241</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.</time_frame>
    <description>Defined as the apparent plasma terminal phase disposition half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl/F of ZSP1241</measure>
    <time_frame>Protocol-defined time points during Cycles 0 (7 days) and 1 (28 days) of treatment per subject.</time_frame>
    <description>Defined as oral dose clearance</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with advanced solid tumors including hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with hepatocellular carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZSP1241</intervention_name>
    <description>ZSP1241 tablets for oral administration.</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2 Cohort A</arm_group_label>
    <arm_group_label>Part 2 Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants are required to meet all the criteria below in order to be included in&#xD;
             the trial:&#xD;
&#xD;
               1. Male or female patient, aged 18 ~ 75 years.&#xD;
&#xD;
               2. Confirmed diagnosis of advanced solid tumors by histological or cytological&#xD;
                  examination, participants have no effective standard anticancer therapy available&#xD;
                  or is intolerant to standard anticancer therapy.&#xD;
&#xD;
               3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
               4. Participants with at least 1 measurable tumor lesion based on RECIST 1.1.&#xD;
&#xD;
               5. Recovery from past medical history of adverse reactions (excluding alopecia and&#xD;
                  neurotoxicity) caused by radiotherapy and/or chemotherapy to NCI CTCAE 5.0 Grade&#xD;
                  ≤ 1 or baseline level.&#xD;
&#xD;
               6. Life expectancy ≥ 12 weeks.&#xD;
&#xD;
               7. Adequate organ function, defined by the following laboratory results, to be&#xD;
                  obtained prior to enrollment:&#xD;
&#xD;
                  Bone marrow function: ANC≥1.5×109/L; HB≥90 g/L; PLT≥75×109/L. Liver function:&#xD;
                  ALT≤2.5×ULN, AST≤2.5×ULN, ALP≤2.5×ULN, TBIL≤1.5×ULN; ALT≤5×ULN, AST≤5×ULN (For&#xD;
                  participants with liver focal masses and metastasis).&#xD;
&#xD;
                  Renal function: creatinine≤1.5×ULN; CL≥ 50 mL/min. Coagulation function:&#xD;
                  INR≤1.5×ULN; INR≤2.3×ULN (For participants with liver focal masses and&#xD;
                  metastasis).&#xD;
&#xD;
               8. Child-Pugh class A (only for hepatocellular carcinoma and cholangiocarcinoma).&#xD;
&#xD;
               9. Participants (including partners) who have no gestation plans and are willing to&#xD;
                  follow reliable contraceptive measures during the study and until 8 months after&#xD;
                  the last dosing.&#xD;
&#xD;
              10. Participants with voluntarily signature Informed Consent Form (ICF) prior to&#xD;
                  screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligible participants must not meet any of the following exclusion criteria:&#xD;
&#xD;
               1. Participants who have intracranial tumor and/or brain metastases with clinical&#xD;
                  symptoms needed treatment are ineligible not including the following :&#xD;
&#xD;
                    1. recovery from the therapy (including radiotherapy and/or surgery) 4 weeks&#xD;
                       before enrollment.&#xD;
&#xD;
                    2. participants with intracranial tumor who are clinically stable during&#xD;
                       screening and enrollment, no need to medication by hormone or&#xD;
                       anticonvulsants, and predicted to be clinically stable during the study.&#xD;
&#xD;
               2. Participants who suffer from chronic and active infective diseases and require&#xD;
                  systemic antibiotic, antifungal, or antiviral treatment except concomitant&#xD;
                  antiviral systemic therapy for chronic hepatitis B or C.&#xD;
&#xD;
               3. Participants with dysphagia.&#xD;
&#xD;
               4. Participants with incontrollable hydrops in third lumen such as malignant pleural&#xD;
                  effusion and ascites.&#xD;
&#xD;
               5. Participants with history of pulmonary fibrosis or interstitial pneumonia&#xD;
                  including pneumoconiosis and radiation pulmonary fibrosis beyond radiation field.&#xD;
&#xD;
               6. Participants who suffer from irritable bowel syndrome and need medication.&#xD;
&#xD;
               7. Participants with any clinically significant gastrointestinal abnormalities such&#xD;
                  as Crohn's disease, ulcerative colitis and subtotal gastrectomy.&#xD;
&#xD;
               8. Participants with major surgery in recent 4 weeks or active peptic ulcer disease&#xD;
                  or unrecovered wound.&#xD;
&#xD;
               9. Participants with history of myocardial infarction or congestive heart-failure&#xD;
                  (CHF) at NYHA≥3 level within 6 months prior to enrollment.&#xD;
&#xD;
              10. Participants with LVEF&lt;50% during screening.&#xD;
&#xD;
              11. Participants with QTcF prolongations in ECG baseline ( QTcF&gt;450ms for males or&#xD;
                  QTcF&gt;470ms for females) or high risk factors leading to QT intervals prolonging&#xD;
                  (including hypokalemia, familial QT interval prolongation syndrome) or a history&#xD;
                  of uncontrollable blood pressure or a history of severe or uncontrollable&#xD;
                  ventricular arrhythmia such as two or three degree atrioventricular block.&#xD;
&#xD;
              12. Participants with medications known as QTc prolongation or TDP ventricular&#xD;
                  tachycardia inducer or strong inhibitors and inducers of CYP3A4 not less than 5&#xD;
                  days or 5 half-times before first dosing ZSP1241.&#xD;
&#xD;
              13. Participants with history of most recently chemotherapy, radiotherapy, or&#xD;
                  non-antibody antitumor biologics within 4 weeks prior to the first ZSP1241&#xD;
                  treatment and last time medication of nitrosoureas, mitomycin C or doxorubicin&#xD;
                  within 6 weeks and latest usage of antibody antitumor biologics within 4 weeks.&#xD;
&#xD;
              14. Participants with current or prior retinal detachment or presently confirmed&#xD;
                  diagnosis keratopathy including but not limited to bullous keratopathy, calcific&#xD;
                  band keratopathy, corneal abrasion, keratohelcosis, keratitis and so on.&#xD;
&#xD;
              15. Participants with history of autoimmune disease.&#xD;
&#xD;
              16. Pregnant or nursing women.&#xD;
&#xD;
              17. Participants who, in the judgment of the investigator, will be unfit for the&#xD;
                  study. ( For reasons such as poor compliance, unsuitable for venous&#xD;
                  catheterization and so on)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruihua Xu, MD</last_name>
    <phone>+862087343333</phone>
    <email>xurh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua XU, MD</last_name>
      <phone>+862087343333</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

